# Celltrion pharmaceutical market expansion

> Live situation record from CLSTR: https://clstr.news/situations/celltrion-pharmaceutical-market-expansion
> Updated: 2026-09-30T22:41:36.000Z. Sources: 7. Developments: 2.

Celltrion has initiated efforts to expand its global pharmaceutical footprint through strategic partnerships and market penetration. The company announced its participation in the CPHI exhibition in Milan to seek new drug pipeline partnerships in areas such as oncology, obesity, and autoimmune diseases, while also aiming to expand its Contract Development and Manufacturing Organization (CDMO) services.

Following these strategic moves, Celltrion has successfully increased its biosimilar market share across several European nations. The company secured significant government tenders in Norway, Finland, and the Netherlands, particularly for its autoimmune disease treatment, Aptozma. Additionally, products such as Omlyclo and Osenvelt have secured sole supply rights or tenders in Denmark and Norway, driven by the company’s established direct sales networks.

## Timeline

### 2026-09-30: Celltrion expands European biosimilar market share through new tenders

Celltrion is expanding its European biosimilar market share, securing major tenders for Aptozma, Omlyclo, and Osenvelt in Norway, Denmark, Finland, and the Netherlands.

2 sources. https://clstr.news/cluster/celltrion-expands-european-biosimilar-market-share-through-new-tenders

### 2026-09-29: Celltrion to seek new drug and CDMO partnerships at CPHI Milan

Celltrion seeks new drug and CDMO partnerships at the CPHI exhibition in Milan, while other Korean firms report expanded distribution and resumed drug supplies.

6 sources. https://clstr.news/cluster/celltrion-to-seek-new-drug-and-cdmo-partnerships-at-cphi-milan

---
Cite as: Celltrion pharmaceutical market expansion. CLSTR, https://clstr.news/situations/celltrion-pharmaceutical-market-expansion